Nicotinic acetylcholine receptor function in the mesolimbic dopamine system

中脑边缘多巴胺系统中烟碱乙酰胆碱受体的功能

基本信息

批准号：
8696030
负责人：
Ryan Michael Drenan
金额：
$ 33.79万
依托单位：
PURDUE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2019-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8696030
关键词：
AMPA Receptors Address Alleles Animals Attenuated Behavior Behavioral Biochemical Biochemistry Brain Cell surface Cells Communities Complement Data Development Dopamine Drosophila acetylcholine receptor alpha-subunit Drug Targeting Electrophysiology (science)FDA approved Future Genetic Glutamates Goals Health Human Injection of therapeutic agent Lead Ligands Measures Mediating Mediator of activation protein Molecular Molecular Probes Mus Neurons Neurotransmitter Receptor Nicotine Nicotine Dependence Nicotinic Receptors Pathway interactions Pharmacology Plastics Property Psychological reinforcement Psychotropic Drugs Public Health Publishing Receptor Activation Rewards Rodent Model Role Signal Pathway Signal Transduction Slice Surface System Techniques Testing Therapeutic Tobacco Dependence Tobacco use United States Ventral Tegmental Area calmodulin-dependent protein kinase II cigarette smoking conditioning design dopaminergic neuron improved in vivo innovation insight loss of function mesolimbic system novel strategies novel therapeutic intervention novel therapeutics patch clamp preference public health relevance receptor receptor function research study response smoking cessation stoichiometry tool varenicline

项目摘要

DESCRIPTION (provided by applicant): Tobacco addiction is a serious threat to public health in the United States and abroad, and development of new therapeutic approaches is a major priority. Nicotine, the primary psychoactive compound in cigarette smoke, activates and/or desensitizes nicotinic acetylcholine receptors (nAChRs) throughout the brain. nAChRs in the mesolimbic dopamine (DA) pathway are crucial for the rewarding and reinforcing properties of nicotine in rodent models, suggesting that they may be key mediators of nicotine's action in humans. Although it is known that alpha4 and alpha6 nAChR subunits are important components of mesolimbic DA pathway nAChRs, the precise composition and/or stoichiometry of nAChRs in this pathway that are sufficient and/or necessary for nicotine reward remains unknown. Furthermore, the changes in the brain following nicotine exposure that give rise to reward behavior are poorly understood. This proposal will test the hypothesis that activation of alpha4alpha6beta2* (*denotes that other subunits may be present in the nAChR pentamer) nAChRs in the mesolimbic DA pathway is sufficient for nicotine's rewarding effects. Confirming or refuting this hypothesis will result in further identification of the relevant nAChR subtypes in the mesolimbic DA pathway that mediate nicotine's biophysical and/or behavioral effects. Using a combination of behavioral, electrophysiological, and biochemical techniques, we will address our hypothesis with three specific aims. In Specific Aim 1, we will test the idea that activation o alpha4alpha6beta2* nAChRs is sufficient for nicotine reward-like behavior. Using mice which express alpha6* nAChRs that are hypersensitive to nicotine, in parallel with a compound with modest functional selectivity for ?6?2* nAChRs, we will determine whether selective activation of these receptors is sufficient for nicotine CPP. In Specific Aim 2, we will use patch clamp electrophysiology to test the hypothesis that stimulation of alpha4alpha6beta2* nAChRs is sufficient to activate ventral tegmental area (VTA) DA neurons and strengthen glutamatergic input to these cells. In Specific Aim 3, we directly measure changes in nAChR and glutamatergic receptor function in DA neurons from animals exposed to nicotine. The proposed studies will enhance our understanding of the key nAChRs in the mesolimbic DA pathway that are involved in nicotine addiction. Identifying the nAChRs that are sufficient for nicotine reward should lead to a more rational and focused effort to develop new smoking cessation therapeutics.